XNCR News and Press, Xencor Inc. From 07/22/19

Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...

Note: This article was first revealed to subscribers to my exclusive marketplace, The Formula , in February when shares of Blueprint were trading < $80. Preface Documents: 10-Q | Company Slides Shares: 48,853,933 | PPS: $100 | Market Cap: $4.8B | Enterprise Value...

Shares of Xencor ( XNCR ) have risen by nearly 400% since its 2013 IPO was priced in the low single digits. On the other hand, over the past 12 months, the stock has risen by just 6% (boosted recently by news that it was joining the S&P SmallCap 600). When the company came to market,...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that Paul Foster, M.D., senior vice president and chief medical officer at Xencor...

Gainers:  Pyxus International (NYSE: PYX ) +28% . Allergan (NYSE: AGN ) +26% . ENDRA Life Sciences (NASDAQ: NDRA ) +23% . Pier 1 Imports (NYSE: PIR ) +18% . Rafael Holdings (NYSEMKT: RFL ) +16% . Riot Blockchain (NASDAQ: RIOT ) +15% . Vislink Technologies (NASDAQ: VISL ) +15% ....

NEW YORK , June 24, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600:   S&P MidCap 400 constituent MarketAxess Holdings Inc. (NASD: MKTX) will replace L3 Technologies Inc. (NYSE: LLL)...

USANA Health Sciences (NYSE: USNA ) is up 6% after hours, and Xencor (NASDAQ: XNCR ) up 5.1% , on news that they're each moving into the S&P SmallCap 600 index . More news on: USANA Health Sciences, Inc., Xencor, Inc., Fidelity Southern Corporation, Healthcare stocks news, Tech sto...

— XmAb22841, a CTLA-4 x LAG-3 bispecific antibody, is Xencor’s third tumor microenvironment (TME) activator to enter clinical development — — Phase 1 study to explore the combination of XmAb22841 with pembrolizumab, an anti-PD-1 immunotherapy, to create trip...

Xencor ( XNCR ) was able to get the FDA to remove a clinical hold for its program using XmAb14045 to treat patients with relapsed/refractory acute myeloid leukemia. This is a big win for the company because many months ago, this program was put at a standstill after the FDA had put a partial...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein, Ph.D., as vice president, business developm...